Virtus LifeSci Biotech Products ETF (BBP)
- Previous Close
57.83 - Open
54.97 - Bid 55.03 x 900
- Ask 55.31 x 800
- Day's Range
55.08 - 55.21 - 52 Week Range
48.65 - 69.12 - Volume
117 - Avg. Volume
3,413 - Net Assets 23.61M
- NAV 55.08
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return -8.22%
- Beta (5Y Monthly) 0.60
- Expense Ratio (net) 0.79%
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Virtus
Fund Family
Health
Fund Category
23.61M
Net Assets
2014-12-16
Inception Date
Performance Overview: BBP
View MoreTrailing returns as of 5/6/2025. Category is Health.
People Also Watch
Holdings: BBP
View MoreTop 10 Holdings (22.92% of Total Assets)
Sector Weightings
Related ETF News
View More
Research Reports: BBP
View MoreDaily – Vickers Top Buyers & Sellers for 02/20/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/05/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Alibaba Earnings: Results in Line; Shares Fairly Valued
Alibaba is the world’s largest online and mobile commerce company as measured by gross merchandise volume. It operates China’s online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.
RatingPrice TargetAmgen Earnings: Maintaining Our $317 Fair Value Following In-Line Quarter; Awaiting MariTide Data
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice Target